Catalyst Pharmaceuticals (CPRX) Current Assets (2010 - 2026)

Catalyst Pharmaceuticals' Current Assets history runs 17 years deep, the most recent figure standing at $940.4 million for Q1 2026.

• Quarterly Current Assets rose 37.14% year-over-year to $940.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $940.4 million (up 37.14% YoY) and the FY2025 annual result came in at $894.0 million, up 43.36% from the prior year.
• Current Assets was $940.4 million for Q1 2026 at Catalyst Pharmaceuticals, up from $894.0 million in the prior quarter.
• Across five years, Current Assets topped out at $940.4 million in Q1 2026 and bottomed at $192.0 million in Q3 2023.
• A 5-year average of $475.6 million and a median of $404.6 million in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2023 — Current Assets slumped 31.63% — and 2024, when it jumped 184.33%.
• Catalyst Pharmaceuticals' Current Assets stood at $320.8 million in 2022, then tumbled by 31.63% to $219.3 million in 2023, then soared by 184.33% to $623.6 million in 2024, then jumped by 43.36% to $894.0 million in 2025, then increased by 5.19% to $940.4 million in 2026.
• Business Quant data shows CPRX's Current Assets at $940.4 million in Q1 2026, $894.0 million in Q4 2025, and $852.5 million in Q3 2025.